NCT04281680View on ClinicalTrials.gov

Impact of Pasireotide on Postoperative Pancreatic Fistulas Following Distal Resections

CompletedOBSERVATIONAL
Enrollment

258

Participants

Timeline

Start Date

July 1, 2014

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Surgical Complications
Interventions
DRUG

Pasireotide 0.9 MG/ML

900-ug pasireotide administered subcutaneously twice daily for a week or until discharged from the hospital

All Listed Sponsors
lead

Helsinki University Central Hospital

OTHER

NCT04281680 - Impact of Pasireotide on Postoperative Pancreatic Fistulas Following Distal Resections | Biotech Hunter | Biotech Hunter